Somatic ATM loss-of-function in mCRPC: PROfound enrolled both germline and somatic ATM in...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-ATM-SOMATIC-PROSTATE |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-PROSTATE |
| Sources | SRC-CIVIC SRC-EAU-PROSTATE-2024 SRC-ESMO-PROSTATE-2024 SRC-NCCN-PROSTATE-2025 |
Actionability Facts
| Biomarker | BIO-HRR-PANEL |
|---|---|
| Variant | ATM somatic loss-of-function |
| Disease | DIS-PROSTATE |
| ESCAT tier | IB |
| Recommended combinations | olaparib monotherapy (post-NHA, FDA), talazoparib + enzalutamide (1L, HRR-mut) |
| Evidence summary | Somatic ATM loss-of-function in mCRPC: PROfound enrolled both germline and somatic ATM in Cohort A; olaparib indication covers both. ESCAT IB / OncoKB Level 1. |
Notes
Reflex germline testing recommended (~10-15% of tumor ATM in prostate are germline).
Used By
No reverse references found in the YAML corpus.